NYSE:BIOA - Bioamber Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.0120 0.00 (0.00 %)
(As of 05/21/2018 02:20 PM ET)
Previous Close$0.0110
Today's Range$0.0070 - $0.0120
52-Week Range$0.0120 - $2.88
Volume2.35 million shs
Average Volume2.97 million shs
Market Capitalization$3.08 million
P/E RatioN/A
Dividend YieldN/A
Beta3.29

About Bioamber (NYSE:BIOA)

Bioamber logoBioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Receive BIOA News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:BIOA
CUSIPN/A
Phone+1-612-7474423

Debt

Debt-to-Equity Ratio0.24
Current Ratio1.08
Quick Ratio0.75

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.27 million
Price / Sales0.19
Cash FlowN/A
Price / CashN/A
Book Value$1.41 per share
Price / Book0.01

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-22,470,000.00
Net Margins-238.43%
Return on Equity-48.72%
Return on Assets-22.92%

Miscellaneous

Employees86
Outstanding Shares129,450,000

Bioamber (NYSE:BIOA) Frequently Asked Questions

What is Bioamber's stock symbol?

Bioamber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."

How were Bioamber's earnings last quarter?

Bioamber Inc (NYSE:BIOA) posted its quarterly earnings results on Tuesday, March, 27th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.11. The biotechnology company earned $5.40 million during the quarter, compared to analysts' expectations of $6.49 million. Bioamber had a negative net margin of 238.43% and a negative return on equity of 48.72%. View Bioamber's Earnings History.

What price target have analysts set for BIOA?

2 brokers have issued 1-year target prices for Bioamber's stock. Their predictions range from $1.00 to $1.75. On average, they expect Bioamber's stock price to reach $1.3750 in the next twelve months. View Analyst Ratings for Bioamber.

Who are Bioamber's key executives?

Bioamber's management team includes the folowing people:
  • Raymond J. Land, Chairman of the Board (Age 72)
  • Richard P. Eno, Chief Financial Officer, Director
  • Mario Settino, Chief Financial Officer
  • Michael A. Hartmann, Executive Vice President (Age 48)
  • James Millis, Chief Technology Officer (Age 59)
  • Robert Frost, Director
  • Kurt W. Briner, Independent Director (Age 70)
  • Heinz Haller, Independent Director (Age 62)
  • Ellen B. Richstone, Independent Director (Age 65)
  • Kenneth W Wall, Independent Director (Age 66)

Has Bioamber been receiving favorable news coverage?

News headlines about BIOA stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioamber earned a news sentiment score of 0.16 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.65 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Bioamber?

Shares of BIOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioamber's stock price today?

One share of BIOA stock can currently be purchased for approximately $0.0120.

How big of a company is Bioamber?

Bioamber has a market capitalization of $3.08 million and generates $8.27 million in revenue each year. Bioamber employs 86 workers across the globe.

How can I contact Bioamber?

Bioamber's mailing address is 3850 Annapolis Ln N Ste 180, PLYMOUTH, MN 55447-5476, United States. The biotechnology company can be reached via phone at +1-612-7474423 or via email at [email protected]


MarketBeat Community Rating for Bioamber (BIOA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  255
MarketBeat's community ratings are surveys of what our community members think about Bioamber and other stocks. Vote "Outperform" if you believe BIOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bioamber (NYSE:BIOA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Bioamber in the last 12 months. Their average twelve-month price target is $1.3750, suggesting that the stock has a possible upside of 11,358.33%. The high price target for BIOA is $1.75 and the low price target for BIOA is $1.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.3750$1.3750$6.50$6.50
Price Target Upside: 11,358.33% upside2,982.96% upside1,429.41% upside1,429.41% upside

Bioamber (NYSE:BIOA) Consensus Price Target History

Price Target History for Bioamber (NYSE:BIOA)

Bioamber (NYSE:BIOA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018HC WainwrightLower Price TargetBuy ➝ Buy$12.00 ➝ $1.75HighView Rating Details
11/10/2017CowenReiterated RatingHold$1.00N/AView Rating Details
3/13/2017AltaCorp CapitalDowngradeOutperform ➝ SpeculativeMediumView Rating Details
8/7/2016Canaccord GenuityReiterated RatingBuy$5.50N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Bioamber (NYSE:BIOA) Earnings History and Estimates Chart

Earnings by Quarter for Bioamber (NYSE:BIOA)

Bioamber (NYSE:BIOA) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS

Bioamber (NYSE BIOA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2018Q4 2017($0.18)($0.07)$6.49 million$5.40 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.21)$3.30 millionViewN/AView Earnings Details
8/3/20176/30/2017($0.17)($0.20)$4.09 million$4.12 millionViewListenView Earnings Details
5/9/20173/31/2017($0.13)($0.31)$3.65 million$2.12 millionViewListenView Earnings Details
3/16/201712/31/2016($0.19)($0.31)$3.77 million$0.63 millionViewN/AView Earnings Details
11/3/2016Q216($0.22)($0.26)$3.75 million$3.66 millionViewN/AView Earnings Details
8/9/2016Q116($0.27)($0.25)$2.37 million$2.50 millionViewN/AView Earnings Details
5/3/2016Q1 2016($0.07)($0.29)$2.25 million$1.46 millionViewN/AView Earnings Details
3/14/2016Q415($0.35)($0.40)$0.98 million$1.11 millionViewN/AView Earnings Details
11/4/2015Q315($0.41)($0.27)$2.30 million$0.35 millionViewN/AView Earnings Details
8/4/2015Q2 2015($0.39)$0.34 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.39)$0.37 millionViewN/AView Earnings Details
3/12/2015Q414($0.39)($0.48)($0.31) millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.40)($0.41)$0.47 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.40)$0.40$0.45 million$0.42 millionViewN/AView Earnings Details
5/8/2014Q1 2014$0.45$0.35 millionViewN/AView Earnings Details
3/13/2014($0.36)($0.45)$0.44 millionViewListenView Earnings Details
11/7/2013Q3 2013($0.37)$0.87 millionViewN/AView Earnings Details
8/12/2013Q2 2013$0.57$1.03 millionViewN/AView Earnings Details
5/15/2013Q1 2013$0.92$0.33 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bioamber (NYSE:BIOA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Bioamber (NYSE BIOA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.33%
Institutional Ownership Percentage: 28.70%
Insider Trading History for Bioamber (NYSE:BIOA)
Institutional Ownership by Quarter for Bioamber (NYSE:BIOA)

Bioamber (NYSE BIOA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2017Kenneth W WallDirectorBuy40,000$0.43$17,200.00170,443View SEC Filing  
8/18/2017Michael A HartmannInsiderBuy10,000$0.48$4,800.00153,476View SEC Filing  
8/9/2017Mario SettinoCFOBuy15,000$0.53$7,950.0030,000View SEC Filing  
11/9/2016George Frederick John GosbeeDirectorBuy25,000$3.87$96,750.0025,000View SEC Filing  
11/8/2016Kurt W BrinerDirectorBuy10,000$3.84$38,400.00152,645View SEC Filing  
5/24/2016Kurt W BrinerDirectorBuy1,000$3.69$3,690.00142,645View SEC Filing  
5/23/2016Kurt W BrinerDirectorBuy21,015$3.61$75,864.15132,730View SEC Filing  
5/11/2016Jean-Francois HucCEOBuy10,000$3.22$32,200.00154,222View SEC Filing  
5/9/2016Kenneth W WallDirectorBuy13,227$3.11$41,135.9731,227View SEC Filing  
5/6/2016Michael A HartmannEVPBuy3,000$3.44$10,320.00125,143View SEC Filing  
12/3/2015Jean-Francois HucCEOSell27,278$8.11$221,224.58144,222View SEC Filing  
12/3/2015Michael A. HartmannEVPSell21,477$8.11$174,178.47123,143View SEC Filing  
8/14/2015Michael A HartmannEVPBuy1,500$6.75$10,125.00View SEC Filing  
8/11/2015Jean-Francois HucCEOBuy4,000$6.18$24,720.00View SEC Filing  
8/10/2015Raymond J LandDirectorBuy1,500$6.71$10,065.00View SEC Filing  
5/6/2015Jean-Francois HucCEOBuy8,800$9.00$79,200.00View SEC Filing  
5/6/2015Kurt W BrinerDirectorBuy10,000$9.00$90,000.00View SEC Filing  
5/6/2015Michael A HartmannEVPBuy1,100$9.00$9,900.00View SEC Filing  
12/11/2014Kenneth W WallDirectorBuy3,000$9.20$27,600.00View SEC Filing  
12/10/2014Kenneth W WallDirectorBuy5,000$9.30$46,500.00View SEC Filing  
11/10/2014Kurt W BrinerDirectorBuy15,000$9.35$140,250.00View SEC Filing  
9/9/2014Kurt W BrinerDirectorBuy5,000$12.00$60,000.00View SEC Filing  
8/25/2014Kurt W BrinerDirectorBuy14,250$11.50$163,875.00View SEC Filing  
8/11/2014Kurt W BrinerDirectorBuy2,980$11.45$34,121.00View SEC Filing  
7/16/2014Jean-Francois HucCEOBuy4,000$12.00$48,000.00View SEC Filing  
7/16/2014Michael A HartmannEVPBuy3,000$12.00$36,000.00View SEC Filing  
5/12/2014Andrew P AshworthCFOBuy3,000$10.00$30,000.00View SEC Filing  
5/12/2014Michael A HartmannEVPBuy2,500$10.05$25,125.00View SEC Filing  
11/14/2013Kurt W BrinerDirectorBuy7,200$6.95$50,040.00View SEC Filing  
9/3/2013Michael A HartmannEVPBuy2,000$4.63$9,260.00View SEC Filing  
8/29/2013Jean-Francois HucCEOBuy5,000$4.25$21,250.00View SEC Filing  
8/15/2013Kurt W BrinerDirectorBuy13,000$5.49$71,370.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bioamber (NYSE BIOA) News Headlines

Source:
DateHeadline
BRIEF-Bioamber Announces Filing For Stay Of Proceedings On CreditorsBRIEF-Bioamber Announces Filing For Stay Of Proceedings On Creditors
www.reuters.com - May 4 at 5:40 PM
BioAmber Announces Filing for Stay of Proceedings on CreditorsBioAmber Announces Filing for Stay of Proceedings on Creditors
finance.yahoo.com - May 4 at 5:39 PM
2018 European Bio-organic Acid Market Analysis by Application, Product Type and Raw Material - Forecast to 2023 ...2018 European Bio-organic Acid Market Analysis by Application, Product Type and Raw Material - Forecast to 2023 ...
www.businesswire.com - May 1 at 8:16 AM
Special Meeting of Stockholders Adjourned to May 18, 2018Special Meeting of Stockholders Adjourned to May 18, 2018
finance.yahoo.com - May 1 at 8:16 AM
Bioamber (BIOA) Scheduled to Post Quarterly Earnings on MondayBioamber (BIOA) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:57 AM
Global Bio-acrylic Acid Market Growth, Trends, and Forecasts 2018-2023 - ResearchAndMarkets.comGlobal Bio-acrylic Acid Market Growth, Trends, and Forecasts 2018-2023 - ResearchAndMarkets.com
www.businesswire.com - April 26 at 5:20 PM
Bioamber (BIOA) PT Set at $3.00 by CowenBioamber (BIOA) PT Set at $3.00 by Cowen
www.americanbankingnews.com - April 17 at 10:21 PM
Contrasting Sigma-Aldrich (SIAL) and Bioamber (BIOA)Contrasting Sigma-Aldrich (SIAL) and Bioamber (BIOA)
www.americanbankingnews.com - March 30 at 1:16 AM
Bioamber (BIOA) Price Target Cut to $1.75 by Analysts at HC WainwrightBioamber (BIOA) Price Target Cut to $1.75 by Analysts at HC Wainwright
www.americanbankingnews.com - March 29 at 12:22 PM
Edited Transcript of BIOA earnings conference call or presentation 28-Mar-18 12:00pm GMTEdited Transcript of BIOA earnings conference call or presentation 28-Mar-18 12:00pm GMT
finance.yahoo.com - March 29 at 8:19 AM
BioAmbers (BIOA) CEO Rick Eno on Q4 2017 Results - Earnings Call TranscriptBioAmber's (BIOA) CEO Rick Eno on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 28 at 5:24 PM
BioAmber Inc. Announces Record Revenues for the Fourth Quarter and Year End 2017BioAmber Inc. Announces Record Revenues for the Fourth Quarter and Year End 2017
www.prnewswire.com - March 27 at 5:19 PM
Sigma-Aldrich (SIAL) & Bioamber (BIOA) Critical AnalysisSigma-Aldrich (SIAL) & Bioamber (BIOA) Critical Analysis
www.americanbankingnews.com - March 17 at 11:24 AM
BioAmber, Inc. to Host Earnings CallBioAmber, Inc. to Host Earnings Call
finance.yahoo.com - March 16 at 8:13 AM
Aqua Concept GmbH Launches coracon® LT EKO, a Performing and Sustainable Heat Transfer Fluid Engineered from BioAmbers Bio Succinic AcidAqua Concept GmbH Launches coracon® LT EKO, a Performing and Sustainable Heat Transfer Fluid Engineered from BioAmber's Bio Succinic Acid
finance.yahoo.com - March 13 at 8:17 AM
BioAmber Announces Webcast of Fiscal Fourth Quarter 2017 Financial ResultsBioAmber Announces Webcast of Fiscal Fourth Quarter 2017 Financial Results
finance.yahoo.com - March 12 at 6:44 PM
Bioamber (BIOA) to Release Quarterly Earnings on WednesdayBioamber (BIOA) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:32 AM
Bioamber (BIOA) Stock Rating Lowered by ValuEngineBioamber (BIOA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 4 at 11:06 PM
Form 25-NSE BioAmber Inc. Filed by: NEW YORK STOCK EXCHANGE LLC - StreetInsider.comForm 25-NSE BioAmber Inc. Filed by: NEW YORK STOCK EXCHANGE LLC - StreetInsider.com
www.streetinsider.com - February 28 at 8:12 AM
BioAmber, Product Development, Financial Review, TSX Issue, Analysts TargetBioAmber, Product Development, Financial Review, TSX Issue, Analysts Target
finance.yahoo.com - February 26 at 5:48 PM
Form SC 13G BioAmber Inc. Filed by: INTRACOASTAL CAPITAL, LLC - StreetInsider.comForm SC 13G BioAmber Inc. Filed by: INTRACOASTAL CAPITAL, LLC - StreetInsider.com
www.streetinsider.com - February 20 at 8:13 AM
Bioamber (BIOA) Upgraded by Zacks Investment Research to HoldBioamber (BIOA) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 19 at 6:58 PM
BioAmber Inc. Receives Notice of Delisting by TSX - PR Newswire (press release)BioAmber Inc. Receives Notice of Delisting by TSX - PR Newswire (press release)
www.prnewswire.com - February 18 at 8:14 AM
BioAmber Inc. Receives Notice of Delisting by TSXBioAmber Inc. Receives Notice of Delisting by TSX
finance.yahoo.com - February 16 at 8:13 AM
Bioamber (BIOA) Upgraded to Hold by ValuEngineBioamber (BIOA) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - February 14 at 11:42 PM
BioAmber Inc. Receives Notice of Delisting Review by TSXBioAmber Inc. Receives Notice of Delisting Review by TSX
finance.yahoo.com - February 14 at 9:18 AM
Bioamber (BIOA) Stock Rating Lowered by Zacks Investment ResearchBioamber (BIOA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 13 at 7:00 PM
BioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public OfferingBioAmber Inc. Announces Registered Direct Offering; Termination of Underwriting Agreement for Previously-Announced Public Offering
finance.yahoo.com - February 9 at 3:50 PM
BRIEF-Bioamber Inc Announces Pricing Of US$10 Mln Underwritten Public OfferingBRIEF-Bioamber Inc Announces Pricing Of US$10 Mln Underwritten Public Offering
www.reuters.com - February 6 at 8:49 AM
Is BioAmber Inc (NYSE:BIOA) A Financially Sound Company?Is BioAmber Inc (NYSE:BIOA) A Financially Sound Company?
finance.yahoo.com - February 6 at 8:49 AM
BioAmber Inc. announces underwritten offeringBioAmber Inc. announces underwritten offering
finance.yahoo.com - February 6 at 8:49 AM
BioAmber Inc. Announces Pricing of US$10 Million Underwritten Public OfferingBioAmber Inc. Announces Pricing of US$10 Million Underwritten Public Offering
finance.yahoo.com - February 6 at 8:49 AM
Bioamber (BIOA) Downgraded by Zacks Investment Research to "Sell"Bioamber (BIOA) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - January 31 at 6:40 PM
Bio-Succinic Acid Demonstrates Substantial Benefits Toward Growth Performance in Animal Feed Commercial TrialBio-Succinic Acid Demonstrates Substantial Benefits Toward Growth Performance in Animal Feed Commercial Trial
finance.yahoo.com - January 29 at 9:10 AM
BRIEF-Bioamber Restructures Its Credit Facility With Its Senior Lenders - ReutersBRIEF-Bioamber Restructures Its Credit Facility With Its Senior Lenders - Reuters
www.reuters.com - January 27 at 3:42 PM
BioAmber (BIOA) Canadian Subsidiary Restructures Credit Facility - StreetInsider.comBioAmber (BIOA) Canadian Subsidiary Restructures Credit Facility - StreetInsider.com
www.streetinsider.com - January 27 at 3:42 PM
Contrasting Chemtura (CHMT) and Bioamber (BIOA)Contrasting Chemtura (CHMT) and Bioamber (BIOA)
www.americanbankingnews.com - January 27 at 11:26 AM
BioAmber restructures its credit facility with its senior lendersBioAmber restructures its credit facility with its senior lenders
finance.yahoo.com - January 26 at 8:43 AM
Global Renewable Chemicals IndustryGlobal Renewable Chemicals Industry
www.bizjournals.com - January 19 at 9:52 AM
Zacks: Analysts Set $6.50 Price Target for Bioamber Inc (BIOA)Zacks: Analysts Set $6.50 Price Target for Bioamber Inc (BIOA)
www.americanbankingnews.com - January 12 at 9:32 AM
Bioamber (BIOA) & AdvanSix (ASIX) Critical AnalysisBioamber (BIOA) & AdvanSix (ASIX) Critical Analysis
www.americanbankingnews.com - January 9 at 11:16 PM
Bioamber (BIOA) Raised to Hold at Zacks Investment ResearchBioamber (BIOA) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 5:40 PM
North America organic acid market is projected to reach $ 3,043.5 million by 2026North America organic acid market is projected to reach $ 3,043.5 million by 2026
www.bizjournals.com - January 5 at 8:23 AM
Bioamber (BIOA) Downgraded by Zacks Investment ResearchBioamber (BIOA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 3 at 12:06 AM
With A -20.78% Earnings Drop Lately, Did BioAmber Inc (NYSE:BIOA) Underperform Its Industry?With A -20.78% Earnings Drop Lately, Did BioAmber Inc (NYSE:BIOA) Underperform Its Industry?
finance.yahoo.com - January 2 at 3:31 PM
Stock Review for Chemicals Investors -- BioAmber, Air Products and Chemicals, Celanese, and Eastman Chemical ... - PR Newswire (press release)Stock Review for Chemicals Investors -- BioAmber, Air Products and Chemicals, Celanese, and Eastman Chemical ... - PR Newswire (press release)
www.prnewswire.com - December 18 at 8:04 AM
 Brokerages Set $6.50 Price Target for Bioamber Inc (BIOA) Brokerages Set $6.50 Price Target for Bioamber Inc (BIOA)
www.americanbankingnews.com - December 13 at 9:18 PM
Bioamber Inc (BIOA) Director Acquires $17,200.00 in StockBioamber Inc (BIOA) Director Acquires $17,200.00 in Stock
www.americanbankingnews.com - December 4 at 9:32 PM
Bioamber (BIOA) Rating Lowered to Strong Sell at ValuEngineBioamber (BIOA) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - December 3 at 10:04 PM
Global Tetrahydrofuran (THF) Markets, 2024: Increasing Focus on Green Chemistry: A Strong Growth Driver for 2-MeTHFGlobal Tetrahydrofuran (THF) Markets, 2024: Increasing Focus on Green Chemistry: A Strong Growth Driver for 2-MeTHF
www.finanznachrichten.de - November 23 at 3:45 PM

SEC Filings

Bioamber (NYSE:BIOA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bioamber (NYSE:BIOA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bioamber (NYSE BIOA) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.